Atgen Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
1,503
1,678
2,513
6,876
4,830
Cost of Goods Sold (COGS) incl. D&A
468
620
842
1,556
1,653
Gross Income
1,034
1,058
1,671
5,320
3,177
SG&A Expense
3,183
6,124
8,049
13,230
19,157
EBIT
2,149
5,066
6,378
-
15,980
Unusual Expense
818
661
1,070
872
2,306
Non Operating Income/Expense
81
4
30
57
202
Interest Expense
134
109
47
40
-
Pretax Income
3,181
5,840
5,374
6,236
15,860
Income Tax
-
-
-
1,399
772
Consolidated Net Income
3,181
5,840
5,374
4,837
16,632
Net Income
3,181
5,840
5,374
4,837
16,632
Net Income After Extraordinaries
3,181
5,840
5,374
4,837
16,632
Net Income Available to Common
3,181
5,840
5,374
4,837
16,632
EPS (Basic)
158.00
290.00
298.50
217.50
721.00
Basic Shares Outstanding
20
20
18
22
23
EPS (Diluted)
157.88
289.91
298.70
217.62
721.26
Diluted Shares Outstanding
20
20
18
22
23
EBITDA
1,739
4,778
6,005
7,400
15,263
Other Operating Expense
-
-
-
78
-
Non-Operating Interest Income
1
1
11
147
465
Equity in Affiliates (Pretax)
-
-
-
2,574
2,164

About Atgen Co.

View Profile
Address
1st & 6th Floor, Health Care Park
Seongnam-si GY 13605
Korea, Republic Of
Employees -
Website http://www.nkvue.com
Updated 09/14/2018
ATGen Co., Ltd. engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. Its products include NK cells under NK Vue brand, recombinant proteins, and monoclonal antibodies. The company was founded on January 14, 2002 and is headquartered at Seongnam-si, South Korea.